13F Holdings
中文EN

HBIO HARVARD BIOSCIENCE INC

Laboratory Analytical Instruments · Nasdaq · SEC CIK 1123494 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2.3%
TTM net income YoY78.1%
TTM EPS YoY173.1%
Revenue 3-yr CAGR-7.4%
Net income 3-yr CAGR—

Margins

Gross margin57.4%
Operating margin-1.8%
Net margin-13.2%
FCF margin-3.5%
EBITDA margin0.3%

Returns

ROE-123.1%
ROA-15.4%
ROIC (approx.)-3.2%
Asset turnover1.17x

Leverage & solvency

Liabilities / assets93.2%
Debt / equity7.28x
Current ratio1.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.06x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue2.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$86.55M$94.14M$112.25M$113.33M$118.90M
Cost of revenue$36.64M$39.37M$46.18M$52.52M$51.25M
Gross profit$49.91M$54.77M$66.07M$60.82M$67.65M
R&D expense$8.82M$10.41M$11.76M$12.33M$10.80M
SG&A expense$17.74M$21.49M$22.76M$24.49M$24.30M
Operating income-$48.58M-$6.21M$1.89M-$6.93M$2.07M
Interest expense$3.60M$3.20M———
Pretax income-$57.39M-$11.66M-$2.56M-$9.18M-$140,000
Income tax-$686,000$740,000$859,000$337,000$148,000
Net income-$56.70M-$12.40M-$3.42M-$9.52M-$288,000
EBITDA-$46.84M-$4.48M$3.37M-$5.48M$3.85M
EPS (basic)-1.28-0.28-0.08-0.23-0.01
EPS (diluted)-1.28-0.28-0.08-0.23-0.01
Weighted avg. shares (diluted)44.39M43.54M42.42M41.41M40.34M
Balance sheet
Cash & equivalents$8.61M$4.11M$4.28M$4.51M$7.82M
Receivables$16.04M$14.87M$16.10M$16.70M$21.83M
Inventory$20.80M$23.25M$24.72M$26.44M$27.59M
Current assets$48.23M$45.12M$49.04M$51.12M$61.58M
PP&E, net$4.79M$5.11M$3.98M$3.37M$3.42M
Goodwill$9.56M$56.32M$57.06M$56.26M$57.69M
Intangibles$7.64M$11.13M$16.04M$21.01M$27.39M
Total assets$80.07M$126.64M$137.37M$145.36M$162.34M
Current liabilities$21.96M$54.96M$26.54M$23.25M$25.32M
Short-term debt$0$36.96M$6.14M$4.09M$3.52M
Long-term debt$35.87M$0$36.96M$43.01M$45.09M
Total debt$35.87M$36.96M$43.09M$47.10M$48.61M
Total liabilities$66.34M$63.30M$64.29M$73.14M$78.94M
Shareholders' equity$13.73M$63.34M$73.07M$72.22M$83.40M
Net debt$27.26M$32.85M$38.81M$42.60M$40.79M
Shares outstanding4.47M44.07M43.39M42.08M41.14M
Cash flow statement
Operating cash flow$6.73M$1.44M$14.03M$1.15M$1.26M
Capital expenditure$1.26M$2.64M$1.79M$1.59M$1.20M
Free cash flow$5.47M-$1.20M$12.24M-$438,000$67,000
Investing cash flow-$1.86M-$1.34M-$1.80M-$1.59M-$1.34M
Financing cash flow-$1.29M-$131,000-$12.13M-$2.84M-$252,000
Depreciation & amortization$1.74M$1.73M$1.47M$1.45M$1.78M
Stock-based compensation$1.85M$4.34M$5.00M$4.41M$4.17M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.